Comparison · NCT00678392-sae
Axitinib 5 mg vs Sorafenib 400 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Axitinib 5 mg vs Sorafenib 400 mg: serious adverse events. Trial comparisons, record NCT00678392-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00678392-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.407 | 0.357 | 0.458 | wilson | |
| Risk in group 2 | 0.358 | 0.31 | 0.409 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0489 | -0.0223 | 0.119 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.943 | 1.37 | log | |
| Odds ratio, group 1 over group 2 | 1.23 | 0.909 | 1.67 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Axitinib 5 mg than on Sorafenib 400 mg | 20.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Axitinib 5 mg | Axitinib (AG-013736) 5 milligram (mg) tablet administered orally twice daily in cycles of 4 weeks. | 146 | 359 | EG000 |
| Group 2 | Sorafenib 400 mg | Sorafenib 400 mg tablet administered orally twice daily in cycles of 4 weeks. | 127 | 355 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From initiation of treatment up to follow-up period (up to 3 years)
Source ClinicalTrials.gov
Trial
- Title
- Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
- NCT number
- NCT00678392
- Phases
- PHASE3
- Conditions
- Kidney Neoplasms
- Interventions
- Axitinib (AG-013736), Sorafenib
- Lead sponsor
- Pfizer
- Results first posted
- 2012-03-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00678392?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00678392-sae